Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
Aim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and methods. All adult Russian patients with a documented...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-11-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4142 |
| _version_ | 1797856703984697344 |
|---|---|
| author | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina |
| author_facet | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina |
| author_sort | M. V. Zhuravleva |
| collection | DOAJ |
| description | Aim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and methods. All adult Russian patients with a documented NYHA class II-IV HFrEF (EF £40%) were considered the target population. The characteristics of the patients corresponded to those of the Russian Hospital Heart Failure Registry (RUS-HFR). The study looked at an increase in the dapagliflozin use in addition to standard therapy by 10% of patients annually in 2021-2023 and calculated the number of deaths that could be prevented. Cardiovascular mortality curve was created by extrapolation of the DAPA-HF study results using the Kaplan-Meier method. Further, the contribution of prevented deaths with dapagliflozin to the achievement of regional and federal targets for reducing cardiovascular mortality was calculated for 1, 2, and 3 years. Results. In case of 10% annual increase in dapagliflozin use in patients with NYHA class II-IV HFrEF, this will allow:— to prevent an additional 1,736 cardiovascular deaths in the first year, achieving the target of federal project on the prevention of cardiovascular diseases in 2021 by 5,9%;— to prevent an additional 3,784 cardiovascular deaths in the second year, achieving the target of federal project on the prevention of cardiovascular diseases in 2022 by 12,9%;— to prevent an additional 5,485 cardiovascular deaths in the third year, achieving the target of federal project on the prevention of cardiovascular diseases in 2023 by 18,7%.Conclusion. The use of dapagliflozin in patients with HFrEF will reduce mortality from cardiovascular diseases. |
| first_indexed | 2024-04-09T20:45:58Z |
| format | Article |
| id | doaj.art-b7da9ff18e4446f8989b8d6d0d051f99 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:45:58Z |
| publishDate | 2020-11-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-b7da9ff18e4446f8989b8d6d0d051f992023-03-29T21:23:36Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-11-01251010.15829/1560-4071-2020-41423086Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseasesM. V. Zhuravleva0S. N. Tereshchenko1I. V. Zhirov2S. V. Villevalde3T. V. Marin4Yu. V. Gagarina5Scientific Centre for Expert Evaluation of Medicinal Products; I. M. Sechenov First Moscow State Medical UniversityNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyAlmazov National Medical Research CenterI. M. Sechenov First Moscow State Medical UniversityI. M. Sechenov First Moscow State Medical UniversityAim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and methods. All adult Russian patients with a documented NYHA class II-IV HFrEF (EF £40%) were considered the target population. The characteristics of the patients corresponded to those of the Russian Hospital Heart Failure Registry (RUS-HFR). The study looked at an increase in the dapagliflozin use in addition to standard therapy by 10% of patients annually in 2021-2023 and calculated the number of deaths that could be prevented. Cardiovascular mortality curve was created by extrapolation of the DAPA-HF study results using the Kaplan-Meier method. Further, the contribution of prevented deaths with dapagliflozin to the achievement of regional and federal targets for reducing cardiovascular mortality was calculated for 1, 2, and 3 years. Results. In case of 10% annual increase in dapagliflozin use in patients with NYHA class II-IV HFrEF, this will allow:— to prevent an additional 1,736 cardiovascular deaths in the first year, achieving the target of federal project on the prevention of cardiovascular diseases in 2021 by 5,9%;— to prevent an additional 3,784 cardiovascular deaths in the second year, achieving the target of federal project on the prevention of cardiovascular diseases in 2022 by 12,9%;— to prevent an additional 5,485 cardiovascular deaths in the third year, achieving the target of federal project on the prevention of cardiovascular diseases in 2023 by 18,7%.Conclusion. The use of dapagliflozin in patients with HFrEF will reduce mortality from cardiovascular diseases.https://russjcardiol.elpub.ru/jour/article/view/4142dapagliflozinheart failuretargetscardiovascular mortalityfederal project on the prevention of cardiovascular diseases |
| spellingShingle | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases Российский кардиологический журнал dapagliflozin heart failure targets cardiovascular mortality federal project on the prevention of cardiovascular diseases |
| title | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| title_full | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| title_fullStr | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| title_full_unstemmed | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| title_short | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| title_sort | effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases |
| topic | dapagliflozin heart failure targets cardiovascular mortality federal project on the prevention of cardiovascular diseases |
| url | https://russjcardiol.elpub.ru/jour/article/view/4142 |
| work_keys_str_mv | AT mvzhuravleva effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases AT sntereshchenko effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases AT ivzhirov effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases AT svvillevalde effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases AT tvmarin effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases AT yuvgagarina effectofdapagliflozininpatientswithheartfailureonreducingcardiovascularmortalityinfederalprojectonthepreventionofcardiovasculardiseases |